Search clinical trials for: open-label ridaforolimus (MK8669)

Total 761 results

Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Prostate Cancer
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC
University of Colorado, Denver; Memorial Sloan Kettering Cancer Center; H. Lee... and other collaborators

Completed

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Solid Tumors
Massachusetts General Hospital
National Center for Complementary and Integrative Health (NCCIH); Harvard University

Completed

Pilot Study of Open-label Placebo to Treat Major Depressive Disorder

Major Depressive Disorder

United States
Mayo Clinic

Completed

Efficacy of Penile Traction Therapy Using a Novel Device

Penile Diseases

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Pfizer
Pfizer

Recruiting

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

United States, Nigeria
Universitätsklinikum Hamburg-Eppendorf

Completed

Non-concealed Placebo Treatment for Menopausal Hot Flushes

Hot Flashes

Germany
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Leiden University

Completed

Reducing Nocebo Effects on Pressure Pain

Pain | Hyperalgesia

Netherlands
University of Nebraska

Recruiting

ADX-629 Therapy for Sjogren-Larsson Syndrome

Sjogren-Larsson Syndrome

United States
OrphAI Therapeutics

Completed

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Oncology

United States
Scion NeuroStim

Enrolling by invitation

STEM-PD Open Label Extension (OLE)

Parkinson Disease | Parkinson's Disease and Parkinsonism

United States
University of California, San Francisco

Recruiting

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents (OLP)

Depression

United States
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Georgetown University
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Terminated

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy (SELECT)

Thymoma | Advanced Thymic Epithelial Tumor

United States
University Hospital, Bordeaux

Not yet recruiting

Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology (MOSES)

Benign Prostatic Hypertrophy | Holmium Laser Enucleation of the Prostate
Studio Osteopatico Busto Arsizio

Recruiting

Open-label Placebo in Manual Therapy

Low Back Pain, Recurrent

Italy
University of Maryland, Baltimore

Not yet recruiting

Placebo Impacts Sleep and Pain Modulation in Chronic Headache

Chronic Pain | Headache
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)

Psoriasis

France
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Mechanisms of Desensitization During Peanut Oral Immunotherapy (PnOIT4)

Food Hypersensitivity

United States
Hospital de Egas Moniz

Completed

Open Label Placebo in the Treatment of Low Back Pain

Chronic Low Back Pain

Portugal
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Solid Tumors

United States
University of California, Los Angeles

Enrolling by invitation

In-patient SCC TMS

Major Depressive Disorder

United States
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

Solid Tumors

United States
ES Therapeutics Australia Pty Ltd

Recruiting

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Drug Resistant Epilepsy

Australia
Menoufia University

Not yet recruiting

Timing of Initiation of Parenteral Nutrition for Critically Ill Children (TPN)

Critical Illness
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Protagonist Therapeutics, Inc.

Enrolling by invitation

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)

Polycythemia Vera

United States
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

Moderate-severe Glabellar Lines
University of North Carolina, Chapel Hill
The Broad Foundation; Crohn's and Colitis Foundation; OpenBiome

Terminated

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

Pouchitis

United States
M.D. Anderson Cancer Center

Recruiting

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Fatigue | Metastatic Cancers

United States
Matthew C. Baker

Withdrawn

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17)

Primary Sjogren's Syndrome

United States
Vanda Pharmaceuticals

Recruiting

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Gastroparesis | Diabetic Gastroparesis | Idiopathic Gastroparesis

United States
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
University of Arkansas

Completed

Walnut Oral Immunotherapy for Tree Nut Allergy (WOIT)

Tree Nut Allergy

United States
University of Pennsylvania

Terminated

rTMS Pilot for Anxiety

Generalized Anxiety Disorder

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
Opsidio, LLC
Innovaderm Research Inc.

Recruiting

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Sanifit Therapeutics S. A.

Completed

Phase 3 Study of SNF472 for Calciphylaxis (Calciphyx)

Calciphylaxis | Calcific Uremic Arteriolopathy

United States, Belgium, United Kingdom, Spain, Germany, Poland
Johns Hopkins University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

CAPABLE Transplant

Depression | Quality of Life | End Stage Renal Disease | Disability Physical

United States
Stanford University

Completed

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD) (aTBS)

Treatment Resistant Depression

United States
Stealth BioTherapeutics Inc.

Terminated

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension (MMPOWER-3)

Primary Mitochondrial Myopathy

United States, Germany, Canada, Italy, United Kingdom, Denmark, Hungary
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 (PATH-2)

Secondary Hyperparathyroidism | End Stage Kidney Disease

United States, Bulgaria, Portugal, Spain, Poland, Serbia
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 (PATH-1)

Secondary Hyperparathyroidism | End-stage Kidney Disease (ESKD)

United States, Bulgaria, Portugal, Spain, Poland, Serbia
Johns Hopkins University
National Institute on Disability, Independent Living, and Rehabilitation... and other collaborators

Completed

CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners

Depression | Quality of Life | Caregiver Burden | Mild Cognitive Impairment | Disability Physical | Dementia, Mild | Impairment, Cognitive

United States
Fiechtner, Justus J., M.D., P.C.
Mallinckrodt

Unknown

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

Psoriatic Arthritis

United States

Search clinical trials for: open-label ridaforolimus (MK8669)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations